MedTrace Logo

Pre-exposure Prophylaxis: A Miracle Drug or a Moral Hazard

NCT04325555 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2647

Last updated 2020-10-14

No results posted yet for this study

Summary

The investigators study the behavioral consequences of Pre-exposure Prophylaxis or PrEP on sexual health behaviors, sexual health outcomes, and partner selection preferences. The study collects observational, self-reported data on PrEP status, PrEP taking-history, PrEP adherence over the last 30 days, STD diagnosis history dating back to January 2015 up to December 2019, sexual health behaviors (e.g., positioning, number of lifetime/recent partners, condom adherence etc.), and various demographic characteristics. The survey finishes with a conjoint experiment which asks respondents to select between two potential partners, and follow-up question about each profiles. Potential partners' characteristics include recreational drug use and condom adherence. Recruitment is conducted via running an ad on Facebook in New York, London, Toronto and Sydney for comparative purposes, as these metro areas have varying levels of PrEP use and accessibility.

Conditions

  • Syphilis
  • Chlamydia
  • Gonorrhea
  • Sexually Transmitted Diseases

Interventions

DRUG

PrEP

The investigators measure self-reported PrEP status as exposure, i.e., PrEP status is not confirmed via matched medical records or any other type of information directly collected form subjects.

Sponsors & Collaborators

  • New York University

    lead OTHER

Principal Investigators

  • Kinga R Makovi, PhD · New York University Abu Dhabi

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-20
Primary Completion
2020-03-15
Completion
2020-03-15

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04325555 on ClinicalTrials.gov